“Exelixis (EXEL) is maintaining the previously provided financial guidance for fiscal year 2025. Net product and total revenues guidance do not currently reflect any revenues resulting from a potential U.S. regulatory approval and commercial launch of CABOMETYX for the treatment of patients with previously treated advanced neuroendocrine tumors. The U.S. Food and Drug Administration is currently reviewing Exelixis’ supplemental New Drug Application for this proposed indication, with a Prescription Drug User Fee Act – PDUFA – target action date of April 3,” the company stated.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- EXEL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Exelixis price target raised to $43 from $42 at Truist
- Exelixis upgraded to Overweight from Equal Weight at Morgan Stanley
- Exelixis announces results from expansion cohort of phase 1b/2 STELLAR-001
- Exelixis reports on subgroup analysis of Phase 3 CABINET study
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue